Jump Financial LLC Acquires Shares of 39,603 Repare Therapeutics Inc. (NASDAQ:RPTX)

Jump Financial LLC acquired a new stake in shares of Repare Therapeutics Inc. (NASDAQ:RPTX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 39,603 shares of the company’s stock, valued at approximately $289,000. Jump Financial LLC owned 0.09% of Repare Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently made changes to their positions in RPTX. Exchange Traded Concepts LLC increased its holdings in Repare Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 13,585 shares of the company’s stock valued at $99,000 after purchasing an additional 3,445 shares during the period. SRS Capital Advisors Inc. increased its stake in shares of Repare Therapeutics by 100.0% during the fourth quarter. SRS Capital Advisors Inc. now owns 10,000 shares of the company’s stock valued at $73,000 after buying an additional 5,000 shares during the period. Raymond James Financial Services Advisors Inc. bought a new position in shares of Repare Therapeutics during the third quarter valued at approximately $149,000. Blackstone Inc. lifted its stake in Repare Therapeutics by 14.9% in the third quarter. Blackstone Inc. now owns 25,957 shares of the company’s stock worth $314,000 after acquiring an additional 3,362 shares during the period. Finally, ARK Investment Management LLC raised its holdings in Repare Therapeutics by 7.7% in the 4th quarter. ARK Investment Management LLC now owns 2,821,560 shares of the company’s stock worth $20,597,000 after purchasing an additional 200,677 shares in the last quarter. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Trading Up 0.6 %

Shares of RPTX stock opened at $3.12 on Monday. Repare Therapeutics Inc. has a 12 month low of $2.98 and a 12 month high of $13.85. The company’s fifty day moving average price is $3.81 and its 200-day moving average price is $5.41. The stock has a market cap of $132.41 million, a PE ratio of -2.84 and a beta of 0.70.

Repare Therapeutics (NASDAQ:RPTX) last released its earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.11). The business had revenue of $13.05 million for the quarter, compared to analysts’ expectations of $15.92 million. Repare Therapeutics had a negative net margin of 46.69% and a negative return on equity of 19.81%. On average, sell-side analysts forecast that Repare Therapeutics Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on RPTX shares. Bloom Burton raised shares of Repare Therapeutics from an “accumulate” rating to a “buy” rating in a research note on Friday, April 19th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a research report on Wednesday, February 21st.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.